SCA
AVXL icon

Snowden Capital Advisors’s Anavex Life Sciences AVXL Stock Holding History

Snowden Capital Advisors’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Sell
40,484
-630
-2% -$1.86K ﹤0.01% 1315
2026
Q1 		$126K Sell
41,114
-1,603
-4% -$6.94K ﹤0.01% 1254
2025
Q4 		$152K Buy
+42,717
New +$262K ﹤0.01% 1238

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Snowden Capital Advisors's AVXL Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Anavex Life Sciences (AVXL) stake by 1.5% in Q2 2026, selling an estimated $1.86K and leaving 40,484 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Snowden Capital Advisors first reported a position in AVXL in Q4 2025 and has held it in 3 quarters since. The position peaked at $152K in Q4 2025. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Snowden Capital Advisors held 40,484 shares of Anavex Life Sciences worth $105K as of Q2 2026.
  • Snowden Capital Advisors sold 630 Anavex Life Sciences shares in Q2 2026, an estimated $1.86K.
  • Anavex Life Sciences made up ﹤0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1315 holding.
  • Snowden Capital Advisors first reported a position in Anavex Life Sciences in Q4 2025 and has held it in 3 quarters since.
  • Snowden Capital Advisors's Anavex Life Sciences position peaked at $152K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.